Latest Rhenman & Partners Asset Management AB Stock Portfolio
Rhenman & Partners Asset Management AB Performance:
2024 Q3: 6.83%YTD: 16.42%2023: 7.45%
Performance for 2024 Q3 is 6.83%, and YTD is 16.42%, and 2023 is 7.45%.
About Rhenman & Partners Asset Management AB and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Rhenman & Partners Asset Management AB reported an equity portfolio of $1.2 Billions as of 30 Sep, 2024.
The top stock holdings of Rhenman & Partners Asset Management AB are BSX, UNH, LLY. The fund has invested 4% of it's portfolio in BOSTON SCIENTIFIC CORP and 3.5% of portfolio in UNITED HEALTH GROUP INC.
The fund managers got completely rid off EDWARDS LIFESCIENCES CORP (EW), PENUMBRA INC (PEN) and STAAR SURGICAL CO CALL (STAA) stocks. They significantly reduced their stock positions in THE CIGNA GROUP (CI), ARVINAS INC (ARVN) and MADRIGAL PHARMACEUTICALS INC (MDGL). Rhenman & Partners Asset Management AB opened new stock positions in NOVO-NORDISK A S, CVS HEALTH CORP (CVS) and HUMANA INC (HUM). The fund showed a lot of confidence in some stocks as they added substantially to BRUKER CORP (BRKR), INSPIRE MED SYS INC (INSP) and APELLIS PHARMACEUTICALS INC (APLS).
The top stock holdings of Rhenman & Partners Asset Management AB are BSX, UNH, LLY. The fund has invested 4% of it's portfolio in BOSTON SCIENTIFIC CORP and 3.5% of portfolio in UNITED HEALTH GROUP INC.
The fund managers got completely rid off EDWARDS LIFESCIENCES CORP (EW), PENUMBRA INC (PEN) and STAAR SURGICAL CO CALL (STAA) stocks. They significantly reduced their stock positions in THE CIGNA GROUP (CI), ARVINAS INC (ARVN) and MADRIGAL PHARMACEUTICALS INC (MDGL). Rhenman & Partners Asset Management AB opened new stock positions in NOVO-NORDISK A S, CVS HEALTH CORP (CVS) and HUMANA INC (HUM). The fund showed a lot of confidence in some stocks as they added substantially to BRUKER CORP (BRKR), INSPIRE MED SYS INC (INSP) and APELLIS PHARMACEUTICALS INC (APLS).
Rhenman & Partners Asset Management AB Annual Return Estimates Vs S&P 500
Our best estimate is that Rhenman & Partners Asset Management AB made a return of 6.83% in the last quarter. In trailing 12 months, it's portfolio return was 27.58%.
New Buys
| Ticker | $ Bought |
|---|---|
| novo-nordisk a s | 11,907,000 |
| cvs health corp | 11,569,900 |
| humana inc | 9,818,940 |
| biontech se | 6,057,270 |
| geron corp | 4,540,000 |
| dianthus therapeutics inc | 4,107,000 |
| arcellx inc | 2,672,320 |
| universal hlth svcs inc | 1,832,080 |
New stocks bought by Rhenman & Partners Asset Management AB
Additions
Additions to existing portfolio by Rhenman & Partners Asset Management AB
Reductions
| Ticker | % Reduced |
|---|---|
| the cigna group | -43.8 |
| arvinas inc | -43.26 |
| madrigal pharmaceuticals inc | -42.26 |
| elevance health inc | -41.14 |
| alnylam pharmaceuticals inc | -41.11 |
| centene corp del | -41.06 |
| annexon inc | -37.78 |
| united health group inc | -30.96 |
Rhenman & Partners Asset Management AB reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| augmedix inc | -880,000 |
| revance therapeutics inc | -1,803,390 |
| edwards lifesciences corp | -9,006,080 |
| staar surgical co call | -3,094,650 |
| penumbra inc | -4,139,310 |
| inari med inc | -963,000 |
Rhenman & Partners Asset Management AB got rid off the above stocks
Sector Distribution
Rhenman & Partners Asset Management AB has about 97.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 97.3 |
| Others | 2.6 |
Market Cap. Distribution
Rhenman & Partners Asset Management AB has about 68.8% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 55.6 |
| MID-CAP | 22.5 |
| MEGA-CAP | 13.2 |
| SMALL-CAP | 6.3 |
| UNALLOCATED | 1.9 |
Stocks belong to which Index?
About 76.8% of the stocks held by Rhenman & Partners Asset Management AB either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| S&P 500 | 53.7 |
| Others | 23.3 |
| RUSSELL 2000 | 23.1 |
Rhenman & Partners Asset Management AB Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB has 95 stocks in it's portfolio. About 30.7% of the portfolio is in top 10 stocks. DXCM proved to be the most loss making stock for the portfolio. PRCT was the most profitable stock for Rhenman & Partners Asset Management AB last quarter.
Last Reported on: 13 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABBV | abbvie inc | 2.84 | 177,000 | 34,954,000 | reduced | -6.35 | ||
| ABC | cencora inc | 0.82 | 45,150 | 10,162,400 | reduced | -12.33 | ||
| ABT | abbott labs | 1.25 | 135,000 | 15,391,400 | reduced | -6.9 | ||
| ACHC | acadia healthcare company inc | 0.54 | 105,750 | 6,705,610 | added | 165 | ||
| ACLX | arcellx inc | 0.22 | 32,000 | 2,672,320 | new | |||
| ALGN | align technology inc | 1.14 | 55,000 | 13,987,600 | reduced | -2.65 | ||
| ALHC | alignment healthcare inc | 1.90 | 1,977,360 | 23,372,400 | added | 20.46 | ||
| ALKS | alkermes plc | 0.30 | 133,000 | 3,722,670 | reduced | -11.33 | ||
| ALNY | alnylam pharmaceuticals inc | 1.12 | 50,350 | 13,847,800 | reduced | -41.11 | ||
| AMGN | amgen inc | 0.08 | 3,000 | 966,630 | reduced | -29.41 | ||
| ANNX | annexon inc | 0.27 | 560,000 | 3,315,200 | reduced | -37.78 | ||
| APLS | apellis pharmaceuticals inc | 0.86 | 367,500 | 10,598,700 | added | 563 | ||
| ARVN | arvinas inc | 0.26 | 130,500 | 3,214,220 | reduced | -43.26 | ||
| AUGX | augmedix inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTR | avantor inc | 0.09 | 44,000 | 1,138,280 | reduced | -26.67 | ||
| AXSM | axsome therapeutics inc | 0.89 | 122,600 | 11,018,100 | reduced | -3.92 | ||
| BBIO | bridgebio pharma inc | 0.55 | 268,000 | 6,823,280 | added | 45.26 | ||
| BDX | becton dickinson & co | 2.20 | 112,500 | 27,123,800 | reduced | -0.44 | ||
| BIIB | biogen inc | 1.06 | 67,100 | 13,006,700 | reduced | -20.87 | ||
| BMRN | biomarin pharmaceutical inc | 2.08 | 364,500 | 25,620,700 | added | 44.93 | ||